Introducing Glycolinkers for the Functionalization of Cytotoxic Drugs and Applications in Antibody-Drug Conjugation Chemistry
- ChemMedChem. 2016 Nov 21;11(22):2501-2505. doi: 10.1002/cmdc.201600372.
- 1. Glykos Finland Ltd., Viikinkaari 6, 00790, Helsinki, Finland.
- 2. Department of Chemistry, University of Helsinki, PO Box 55, A. I. Virtasen aukio 1, 00014, Helsinki, Finland.
Antibody-drug conjugates (ADCs) are promising alternatives to naked antibodies for selective drug-delivery applications and treatment of diseases such as Cancer. Construction of ADCs relies upon site-selective, efficient and mild conjugation technologies. The choice of a chemical linker is especially important, as it affects the overall properties of the ADC. We envisioned that hydrophilic bifunctional chemical linkers based on carbohydrates would be a useful class of derivatization agents for the construction of linker-drug conjugates and ADCs. Herein we describe the synthesis of carbohydrate-based derivatization agents, glycolinker-drug conjugates featuring the tubulin inhibitor monomethyl Auristatin E and an ADC based on an anti-EGFR antibody. In addition, an initial in vitro cytotoxicity evaluation of the individual components and the ADC is provided against EGFR-positive Cancer cells.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: ADC LinkersResearch Areas: Cancer